Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Guardian - UK

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings of 75 cents per share.

Benzinga

Self-Made Millionaire Shares 5 European Stocks Every Smart Person Is Buying Now

GOBankingRates spoke with a self-made millionaire and investing expert to determine the best European stocks to consider buying in 2025.

GOBankingRates

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

On Friday, BioNTech SE (NASDAQ:BNTX) and its partner Duality Biologics (Suzhou) Co., Ltd. released topline data from a Phase 3 trial in China evaluating trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) for HER2-positive unresectable or metastatic breast cancer patients who have previously received trastuzumab and a taxane-based chemotherapy.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Evening Standard

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

Evening Standard

Patients to be fast-tracked on to new head and neck cancer vaccine trial

The jab uses mRNA technology to train the immune system to fight cancer.

Evening Standard

‘Game-changing’ cancer vaccine trial to begin on NHS

The jab uses mRNA technology to train the immune system to fight cancerous cells

The Independent UK

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (NASDAQ:BNTX) reported a narrower loss for the second quarter on Monday.

Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

Evening Standard

Vaccine maker’s £1bn UK investment to create ‘hundreds of high-skilled jobs’

BioNTech developed mRNA vaccines, and cancer immunotherapies notably used to tackle Covid-19.

Benzinga

Why Is BioNTech Stock Trading Higher On Friday?

BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients.

The Guardian - UK

US inflation rises to 2.6% in October; Post Office closures put 2,000 jobs at risk – as it happened

Inflation figures closely watched by US Federal Reserve; core inflation holds steady at 3.3%

Get all your
news in one place.

100’s of premium titles.
One news app.

Al Jazeera

Mpox crisis: Why do African countries struggle to make or buy vaccines?

African countries produce less than 2 percent of the vaccines the continent needs, experts say.

The Guardian - UK

World-first lung cancer vaccine trials launched across seven countries

First patient in UK gets dose of jab designed to kill most common form of lung cancer – and stop it coming back

The Independent UK

Lung cancer vaccine: Breakthrough jab could improve survival rates

The vaccine, known as BNT116, utilises messenger RNA (mRNA), the same technology used in the Covid jab

The Independent UK

Lung cancer vaccine: How does it work?

The first UK patient received the jab at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

The Guardian - UK

NHS patients in England to be offered trials for world-first cancer vaccine

Jab personalised for individual’s tumours hailed as ‘gamechanger’ amid high hopes of stopping disease returning

Kiplinger

The Fight Against Cancer Enters a New Phase

Breakthrough treatments hold promise for patients and investors.

International Business Times

InstaDeep CEO Takes AI From Tunis To London

Karim Beguir launched the artificial intelligence start-up InstaDeep in Tunisia in 2014 with just two computers and $2,000.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.